JP2004525174A5 - - Google Patents

Download PDF

Info

Publication number
JP2004525174A5
JP2004525174A5 JP2002579437A JP2002579437A JP2004525174A5 JP 2004525174 A5 JP2004525174 A5 JP 2004525174A5 JP 2002579437 A JP2002579437 A JP 2002579437A JP 2002579437 A JP2002579437 A JP 2002579437A JP 2004525174 A5 JP2004525174 A5 JP 2004525174A5
Authority
JP
Japan
Prior art keywords
optionally substituted
compound
formula
nhc
nhr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002579437A
Other languages
English (en)
Japanese (ja)
Other versions
JP4366079B2 (ja
JP2004525174A (ja
Filing date
Publication date
Priority claimed from GBGB0108876.4A external-priority patent/GB0108876D0/en
Application filed filed Critical
Publication of JP2004525174A publication Critical patent/JP2004525174A/ja
Publication of JP2004525174A5 publication Critical patent/JP2004525174A5/ja
Application granted granted Critical
Publication of JP4366079B2 publication Critical patent/JP4366079B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002579437A 2001-04-09 2002-04-08 ビピペリジニル誘導体およびケモカインレセプターインヒビターとしてのそれらの使用 Expired - Fee Related JP4366079B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0108876.4A GB0108876D0 (en) 2001-04-09 2001-04-09 Organic Compounds
PCT/EP2002/003871 WO2002081449A1 (en) 2001-04-09 2002-04-08 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors

Publications (3)

Publication Number Publication Date
JP2004525174A JP2004525174A (ja) 2004-08-19
JP2004525174A5 true JP2004525174A5 (https=) 2005-06-09
JP4366079B2 JP4366079B2 (ja) 2009-11-18

Family

ID=9912541

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002579437A Expired - Fee Related JP4366079B2 (ja) 2001-04-09 2002-04-08 ビピペリジニル誘導体およびケモカインレセプターインヒビターとしてのそれらの使用

Country Status (27)

Country Link
US (1) US20040142920A1 (https=)
EP (1) EP1379504B1 (https=)
JP (1) JP4366079B2 (https=)
KR (1) KR100616039B1 (https=)
CN (1) CN100469767C (https=)
AR (1) AR035815A1 (https=)
AT (1) ATE446950T1 (https=)
AU (1) AU2002302511B2 (https=)
BR (1) BR0208741A (https=)
CA (1) CA2439241C (https=)
CZ (1) CZ20032723A3 (https=)
DE (1) DE60234167D1 (https=)
EC (1) ECSP034765A (https=)
ES (1) ES2335393T3 (https=)
GB (1) GB0108876D0 (https=)
HU (1) HUP0303724A3 (https=)
IL (1) IL157428A0 (https=)
MX (1) MXPA03009220A (https=)
NO (1) NO20034324D0 (https=)
NZ (1) NZ528712A (https=)
PE (1) PE20021004A1 (https=)
PL (1) PL363011A1 (https=)
PT (1) PT1379504E (https=)
RU (1) RU2296751C2 (https=)
SK (1) SK12422003A3 (https=)
WO (1) WO2002081449A1 (https=)
ZA (1) ZA200306432B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040013090A (ko) 2001-07-02 2004-02-11 아스트라제네카 아베 케모킨 수용체 활성의 조절자로서 유용한 피페리딘 유도체
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AR036366A1 (es) 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0202838D0 (sv) * 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
EP1693061A1 (en) * 2002-10-04 2006-08-23 Ucb, S.A. Use of 4-aminoderivatives for the preparation of a medicament for treating neurological diseases
GB0223223D0 (en) 2002-10-07 2002-11-13 Novartis Ag Organic compounds
AU2003300911A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
US20070043079A1 (en) * 2003-04-18 2007-02-22 Hiromu Habashita Heterocyclic compound containing nitrogen atom and use thereof
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
EP1633737A1 (en) * 2003-06-13 2006-03-15 Schering Aktiengesellschaft Quinolyl amide derivatives as ccr-5 antagonists
CN1898231B (zh) 2003-11-03 2010-10-27 先灵公司 用作趋化因子受体抑制剂的双六氢吡啶衍生物
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
EP1844037A1 (en) * 2005-01-20 2007-10-17 Pfizer Limited Chemical compounds
WO2007011293A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
AR064181A1 (es) * 2006-12-06 2009-03-18 Genzyme Corp Compuestos de union a receptores de quimioquinas
CA2756870A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted indolo-pyridinone compounds
BR112013023050A8 (pt) 2011-03-09 2018-09-25 G Pestell Richard antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um composto candidato, para produzir in vitro células epiteliais primárias, para diagnosticar câncer de próstata, para selecionar um tratamento para um indivíduo tendo um câncer/tumor de próstata, linhagem de célula, e, modelo animal
AU2013262977A1 (en) 2012-05-14 2015-01-22 Prostagene, Llc Using modulators of CCR5 for treating cancer
WO2015091420A1 (de) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituierte bipiperidinyl-derivate als adrenrezeptor alpha 2c antagonisten
CN106029648A (zh) 2013-12-19 2016-10-12 拜耳制药股份公司 作为肾上腺素能受体α2C拮抗剂的取代的联哌啶基衍生物
AP2016009276A0 (en) 2013-12-19 2016-06-30 Bayer Pharma AG Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists
SG11201604949XA (en) 2013-12-19 2016-07-28 Bayer Pharma AG Substituted piperidinyl-tetrahydroquinolines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676054B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
TW531537B (en) * 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) * 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
DE59711622D1 (de) * 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE19637043A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel und Reagenzien
DE19643331A1 (de) * 1996-10-21 1998-04-23 Thomae Gmbh Dr K 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
HK1039330B (en) * 1999-05-04 2005-12-09 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
CO5180558A1 (es) * 1999-06-11 2002-07-30 Merck & Co Inc Derivados de n-[3-((piperidin-1-il)metil)-4-(fenil o hetero- ciclil)ciclopent-1-il]]amina utiles como moduladores de actividad del receptor de la quimioquina
WO2001098268A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
EP1322628A2 (en) * 2000-09-14 2003-07-02 Schering Corporation Substituted urea neuropeptide y y5 receptor antagonists
AR036366A1 (es) * 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
GB0223223D0 (en) * 2002-10-07 2002-11-13 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
JP2004525174A5 (https=)
RU2003130642A (ru) Бипиперидинильные производные и их применение в качестве ингибиторов хемокиновых рецепторов
RU2309951C2 (ru) Производные никотинамида, способы их получения, фармацевтическая композиция на их основе и применение
JP2005505618A5 (https=)
JP2021501756A5 (https=)
JP2005509622A5 (https=)
CY1107974T1 (el) Παραγωγα κινολινης και κιναζολινης εχοντα συναφεια προς τους υποδοχεις τυπου 5ht1
JP2010532387A5 (https=)
JP2009504763A5 (https=)
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
JP2003500404A5 (https=)
JP2011530500A5 (https=)
RU2009105826A (ru) 2,4-ди(ариламино)питимидин-5-карбоксамидные соединения в качестве ингибиторов jak-киназ
JP2005511532A5 (https=)
MX2010008101A (es) Derivados de indol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un silanilo, su preparacion y su aplicacion en terapeutica.
JP2005519932A5 (https=)
JP2010511626A5 (https=)
SI3106463T1 (en) Compounds of substituted pyrazolo (1,5-) pyrimidine as inhibitors of TRK kinase
CA2545427A1 (en) Selective kinase inhibitors
JP2015522650A5 (https=)
GB0128499D0 (en) Therapeutic agents
JP2005511698A5 (https=)
RU2011105810A (ru) Азотсодержащие бициклические гетероциклические соединения
YU73502A (sh) Farmaceutski aktivni derivati pirolidina
JP2012513390A5 (https=)